FaramarzNaeimMD
Pathology • Los Angeles, CAHematopathology, Anatomic Pathology, Clinical Pathology
Member, JCCC Clinical/Translational, UCLA School of Medicine
Dr. Naeim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Ave
Ste B186 CHS
Los Angeles, CA 90095Phone+1 310-794-8285
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pathology-Anatomic and Clinical, 1971 - 1973
Boston University Medical CenterResidency, Pathology-Anatomic and Clinical, 1969 - 1971
Greater Baltimore Medical CenterInternship, Transitional Year, 1968 - 1969
Tehran University of Medical Sciences School of MedicineClass of 1965
Certifications & Licensure
CA State Medical License 1973 - 2026
American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 41 citationsSunitinib Inhibits MEK/ERK and SAPK/JNK Pathways and Increases Sodium/Iodide Symporter Expression in Papillary Thyroid CancerMike S. Fenton, Kenneth M. Marion, Andrew K. Salem, Rachel Hogen, Faramarz Naeim
Thyroid. 2010-09-08 - Suppression of lymphoblastoid cell line proliferation by antisera to HLA-DR and other HLA antigens.Richard A. Gatti, Martin Cousineau, Faramarz Naeim, Wolfgang Leibold
Tissue Antigens. 2008-12-11 - 9 citationsIndomethacin Inhibits Cell Growth of Medullary Thyroid Carcinoma by Reducing Cell Cycle Progression into S PhaseChisato Tomoda, Farhad Moatamed, Faramarz Naeim, Jerome M. Hershman, Masahiro Sugawara
Experimental Biology and Medicine. 2008-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
